Response to Comments: Genomic Sequence Analysis Panels in the Treatment of Acute Myelogenous Leukemia (AML)

This document is a response to public comments on the Genomic Sequence Analysis Panels LCD for Acute Myelogenous Leukemia (AML) and does not state clinical coverage criteria. It records that the official notice period began December 15, 2016 and that the final determination became effective February 1, 2017.

"Final LCD notice period began December 15, 2016 and the final determination became effective February 1, 2017."

Sign up to see full coverage criteria, indications, and limitations.